• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Pasi A. Janne, MD, PhD

Publications

  • Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA.Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M.Cell Rep. 2014 Jun 11.
    24931608
  • Okumura S, Janne PA.Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers.Clin Cancer Res. 2014 Jun 6.
    24907112
  • Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, Lawrence M, Lichtenstein LT, Gentry JG, Huang FW, Fostel J, Farlow D, Barbie D, Gandhi L, Lander ES, Gray SW, Joffe S, Janne P, Garber J, MacConaill L, Lindeman N, Rollins B, Kantoff P, Fisher SA, Gabriel S, Getz G, Garraway LA.Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Nat Med. 2014 Jun;20(6):682-8.
    24836576
  • Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, Herter-Sprie GS, Akbay EA, Tchaicha JH, Altabef A, Reibel JB, Walton Z, Ji H, Watanabe H, Jänne PA, Castrillon DH, Rustgi AK, Bass AJ, Freeman GJ, Padera RF, Dranoff G, Hammerman PS, Kim CF, Wong KK.Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression.Cancer Cell. 2014 May 12;25(5):590-604.
    24794706
  • Sacher AG, Jänne PA, Oxnard GR.Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.Cancer. 2014 Apr 17.
    24752335
  • Muvaffak A, Pan Q, Yan H, Fernandez R, Lim J, Dolinski B, Nguyen TT, Strack P, Wu S, Chung R, Zhang W, Hulton C, Ripley S, Hirsch H, Nagashima K, Wong KK, Janne PA, Seidel-Dugan C, Zawel L, Kirschmeier PT, Middleton RE, Morris EJ, Wang Y.Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3.Mol Cancer Res. 2014 Apr 21.
    24752990
  • Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, Perrino M, Siracusano L, Di Tommaso L, Infante M, Alloisio M, Roncalli M, Scorsetti M, Jänne PA, Santoro A, Varella-Garcia M.Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease.PLoS ONE. 2014;9(4):e95303.
    24736592
  • Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, Ruiz-Garcia A, Letrent S, Liang J, Taylor I, O'Connell JP, Jänne PA.A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.Cancer. 2014 Apr 15;120(8):1145-54.
    24501009
  • Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA.Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA.Clin Cancer Res. 2014 Mar 15;20(6):1698-705.
    24429876
  • Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, Reibel JB, Janne PA, Sharpless NE, Engelman JA, Shapiro GI, Kung AL, Wong KK.Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.Clin Cancer Res. 2014 Mar 1;20(5):1204-11.
    24327273
  • Jänne PA, Cohen RB, Laird AD, Macé S, Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martinez P, Felip E.Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.J Thorac Oncol. 2014 Mar;9(3):316-23.
    24496004
  • de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.J Thorac Oncol. 2014 Feb;9(2):248-53.
    24419423
  • Jänne PA, Paz-Ares L, Oh Y, Eschbach C, Hirsh V, Enas N, Brail L, von Pawel J.Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.J Thorac Oncol. 2014 Jan;9(1):126-31.
    24346102
  • Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK.Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors.Cancer Discovery. 2013 Nov 22.
    24078774
  • Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Jänne PA, Meyerson M, Marto JA, Engen JR, Gray NS.Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor.Angew Chem Int Ed Engl. 2013 Nov 20.
    24259466
  • Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ, Jänne PA, Wong KK, Meyerson M.Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.Cancer Res. 2013 Nov 15;73(22):6770-9.
    24063894
  • Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park SI, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.Nat Med. 2013 Nov;19(11):1469-72.
    24162815
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE.Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.Cancer. 2013 Nov 1;119(21):3761-8.
    23922022
  • Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ.ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.Am J Surg Pathol. 2013 Sep;37(9):1441-9.
    23887156
  • Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA.Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.Clin Cancer Res. 2013 Aug 15;19(16):4532-40.
    23833300
  • Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK.Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.Cancer Discovery. 2013 Aug;3(8):870-9.
    23715154
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE.Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.J Thorac Oncol. 2013 Aug;8(8):1059-68.
    23787800
  • Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE.RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.AJR Am J Roentgenol. 2013 Jul;201(1):W64-71.
    23789698
  • Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med. 2013 Jun 20;368(25):2385-94.
    23724913
  • LoRusso P, Jänne PA, Oliveira M, Rizvi N, Malburg L, Keedy V, Yee L, Copigneaux C, Hettmann T, Wu CY, Ang A, Halim AB, Beckman RA, Beaupre D, Berlin J.Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.Clin Cancer Res. 2013 Jun 1;19(11):3078-87.
    23591447
  • Shepherd FA, Domerg C, Hainaut P, Jänne PA, Pignon JP, Graziano S, Douillard JY, Brambilla E, Le Chevalier T, Seymour L, Bourredjem A, Le Teuff G, Pirker R, Filipits M, Rosell R, Kratzke R, Bandarchi B, Ma X, Capelletti M, Soria JC, Tsao MS.Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.J Clin Oncol. 2013 Apr 29.
    23630215
  • Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS.Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR.Cancer Res. 2013 Apr 15;73(8):2574-2586.
    23436801
  • Oxnard GR, Jänne PA.Power in Numbers: Meta-analysis to Identify Inhibitor-Sensitive Tumor Genotypes.Clin Cancer Res. 2013 Apr 1;19(7):1634-6.
    23403632
  • Oxnard GR, Binder A, Jänne PA.New targetable oncogenes in non-small-cell lung cancer.J Clin Oncol. 2013 Mar 10;31(8):1097-104.
    23401445
  • Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS.Epidermal growth factor receptor inhibition in lung cancer: status 2012.J Thorac Oncol. 2013 Mar;8(3):373-84.
    23370315
  • Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE.Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.Lung Cancer. 2013 Mar;79(3):283-8.
    23254265
  • Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA.Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.Cancer Res. 2013 Jan 15;73(2):834-43.
    23172312
  • Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA.Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.J Thorac Oncol. 2013 Feb;8(2):179-84.
    23328547
  • Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L.Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.Lancet Oncol. 2013 Jan;14(1):38-47.
    23200175
  • Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.The introduction of systematic genomic testing for patients with non-small-cell lung cancer.J Thorac Oncol. 2012 Dec;7(12):1767-74.
    23154547
  • Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Cancer Discovery. 2012 Oct;2(10):934-47.
    22961667
  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012 Oct;13(10):1011-9.
    22954507
  • Oxnard GR, Jänne PA.KRAS wild-type lung cancer: a moving target in an era of genotype migration.J Clin Oncol. 2012 Sep 20;30(27):3322-4.
    22869875
  • Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M.Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.Cell. 2012 Sep 14;150(6):1107-20.
    22980975
  • Stumpfova M, Jänne PA.Zeroing in on ROS1 rearrangements in non-small cell lung cancer.Clin Cancer Res. 2012 Aug 15;18(16):4222-4.
    22859716
  • Gandhi L, Jänne PA.Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target.Clin Cancer Res. 2012 Jul 15;18(14):3737-42.
    22547770
  • Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE.Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.J Clin Oncol. 2012 Jul 10;30(20):2509-15.
    22665541
  • Deng X, Zhou W, Weisberg E, Wang J, Zhang J, Sasaki T, Nelson E, Griffin JD, Jänne PA, Gray NS.An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.Bioorg Med Chem Lett. 2012 Jul 15;22(14):4579-84.
    22727638
  • Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, Padera R, Engelman JA, Jänne PA, Shapiro GI, Shimamura T, Wong KK.Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.Cancer Res. 2012 Jul 1;72(13):3302-11.
    22552292
  • Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA.Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.J Clin Oncol. 2012 Jun 10;30(17):2063-9.
    22547605
  • Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Jänne PA, Kuang Y, Yanagita M, Wang L, Berkowitz JA, Distel RJ, Cayre YE.A new device for rapid isolation by size and characterization of rare circulating tumor cells.Anticancer Res. 2011 Feb;31(2):427-41.
    21378321
  • Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD.Imaging of lung cancer in the era of molecular medicine.Acad Radiol. 2011 Apr;18(4):424-36.
    21277232
  • Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH.Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors.Clin Cancer Res. 2011 Mar 1;17(5):1131-1139.
    21220471
  • Li J, Jänne PA, Makrigiorgos GM.Biotinylated Probe Isolation of Targeted Gene Region Improves Detection of T790M Epidermal Growth Factor Receptor Mutation via Peptide Nucleic Acid-Enriched Real-Time PCR.Clin Chem. 2011 Feb 16.
    21325655
  • Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Jänne PA, Engelman JA.Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.Cancer Res. 2011 Feb 1;71(3):1081-91.
    21266357
  • Zhou W, Ercan D, Jänne PA, Gray NS.Discovery of selective irreversible inhibitors for EGFR-T790M.Bioorg Med Chem Lett. 2011 Jan 15;21(2):638-43.
    21208802
  • Ortiz TM, Cohen DW, Kent MS, Jänne PA, Costa DB.KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma.J Thorac Oncol. 2011 Jan;6(1):220-2.
    21178719
  • Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Cancer Res. 2010 Dec 15;70(24):10038-43.
    21030459
  • Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE.CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.Acad Radiol. 2011 Jan;18(1):54-62.
    21036632
  • Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Aldelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman CL, Park SI, Kim HR, Padera RF, Marto J, Gray N, Kung AL, Shapiro GI, Janne PA, Wong KK.Inhibition of ALK, PI3K/MEK and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene.Cancer Res. 2010 Dec 1;70(23):9827-36.
    20952506
  • Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R.Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer.J Clin Oncol. 2010 Nov 20;28(33):4953-60.
    20940188
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010 Oct 28;363(18):1693-703.
    20979469
  • Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.N Engl J Med. 2010 Oct 28;363(18):1727-33.
    20979472
  • Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.Mol Cancer Ther. 2010 Oct;9(10):2785-92.
    20716641
  • Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL.A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.J Thorac Oncol. 2010 Oct;5(10):1655-61.
    20736856
  • Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE, .Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.J Thorac Oncol. 2010 Sep;5(9):1382-90.
    20686428
  • Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD.New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.AJR Am J Roentgenol. 2010 Sep;195(3):W221-8.
    20729419
  • Sasaki T, Rodig SJ, Chirieac LR, Jänne PA.The biology and treatment of EML4-ALK non-small cell lung cancer.Eur J Cancer. 2010 Jul;46(10):1773-80. Review.
    20418096
  • Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley P, Adamia S, Wu C, Gray N, Griffin JD.Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.Blood. 2010 May 27;115(21):4206-16.
    20299508
  • Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA, Lindeman NI.EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.Am J Clin Pathol. 2010 Jun;133(6):922-34.
    20472851
  • Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE.Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.Br J Cancer. 2010 May 11;102(10):1495-502.
    20461092
  • Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA.Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.Oncogene. 2010 Apr 22;29(16):2346-56.
    20118985
  • Qin W, Kozlowski P, Taillon BE, Bouffard P, Holmes AJ, Janne P, Camposano S, Thiele E, Franz D, Kwiatkowski DJ.Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex.Hum Genet. 2010 Mar;127(5):573-82.
    20165957
  • Cichowski K, Jänne PA.Drug discovery: inhibitors that activate.Nature. 2010 Mar 18;464(7287):358-9.
    20237552
  • Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Jänne PA, Iafrate AJ, Rodig SJ.A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.Clin Cancer Res. 2010 Mar 1;16(5):1561-71.
    20179225
  • Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.Cancer Sci. 2010 Jan;101(1):167-72.
    19804422
  • Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M.The landscape of somatic copy-number alteration across human cancers.Nature. 2010 Feb 18;463(7283):899-905.
    20164920
  • Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.Cancer Cell. 2010 Jan 19;17(1):77-88.
    20129249
  • Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.J Clin Oncol. 2010 Jan 10;28(2):357-60.
    19949011
  • Cortot AB, Jänne PA.Histology... For want of anything better?.Oncology (Huntingt). 2009 Nov 30;23(13):1140-1.
    20043462
  • Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA.Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.Nature. 2009 Dec 24;462(7276):1070-4.
    20033049
  • Hammerman PS, Jänne PA, Johnson BE.Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Clin Cancer Res. 2009 Dec 15;15(24):7502-7509.
    20008850
  • Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR.Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.Cancer Res. 2009 Nov 1;69(21):8341-8.
    19826035
  • Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR.Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.Cancer Res. 2009 Nov 1;69(21):8341-8348.
  • Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM.Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.Cancer. 2009 Sep 15;115(18):4156-66.
    19551884
  • Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ.Integration of molecular profiling into the lung cancer clinic.Clin Cancer Res. 2009 Sep 1;15(17):5317-22.
    19706816
  • Jänne PA, Gray N, Settleman J.Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.Nat Rev Drug Discov. 2009 Sep;8(9):709-23. Review.
    19629074
  • Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res. 2009 Aug 15;15(16):5216-23.
    19671850
  • Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE.Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.Clin Cancer Res. 2009 Aug 15;15(16):5267-73.
    19671843
  • Mukohara T,Shimada H,Ogasawara N,Wanikawa R,Shimomura M,Nakatsura T,Ishii G,Park JO,Janne PA,Saijo N,Minami H.Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.Cancer Lett. 2009 Sep 8;282(1):14-24.
    19345478
  • Park S,Holmes-Tisch AJ,Cho EY,Shim YM,Kim J,Kim HS,Lee J,Park YH,Ahn JS,Park K,Janne PA,Ahn MJ.Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer.J Thorac Oncol. 2009 Jul;4(7):809-15.
    19487967
  • Naumov GN,Nilsson MB,Cascone T,Briggs A,Straume O,Akslen LA,Lifshits E,Byers LA,Xu L,Wu HK,Janne P,Kobayashi S,Halmos B,Tenen D,Tang XM,Engelman J,Yeap B,Folkman J,Johnson BE,Heymach JV.Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.Clin Cancer Res. 2009 May 15;15(10):3484-94.
    19447865
  • Kuang Y,Rogers A,Yeap BY,Wang L,Makrigiorgos M,Vetrand K,Thiede S,Distel RJ,Janne PA.Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.Clin Cancer Res. 2009 Apr 15;15(8):2630-6.
    19351754
  • Smouse JH,Cibas ES,Janne PA,Joshi VA,Zou KH,Lindeman NI.EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer.Cancer Cytopathol. 2009 Feb 25;117(1):67-72.
    19347832
  • Wong KK,Fracasso PM,Bukowski RM,Lynch TJ,Munster PN,Shapiro GI,Janne PA,Eder JP,Naughton MJ,Ellis MJ,Jones SF,Mekhail T,Zacharchuk C,Vermette J,Abbas R,Quinn S,Powell C,Burris HA.A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.Clin Cancer Res. 2009 Apr 1;15(7):2552-8.
    19318484
  • Li J,Wang L,Janne PA,Makrigiorgos GM.Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR.Clin Chem. 2009 Apr;55(4):748-56.
    19233916
  • Okabe T,Okamoto I,Tsukioka S,Uchida J,Hatashita E,Yamada Y,Yoshida T,Nishio K,Fukuoka M,Janne PA,Nakagawa K.Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.Clin Cancer Res. 2009 Feb 1;15(3):907-13.
    19188161
  • Costa DB,Nguyen KS,Cho BC,Sequist LV,Jackman DM,Riely GJ,Yeap BY,Halmos B,Kim JH,Janne PA,Huberman MS,Pao W,Tenen DG,Kobayashi S.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Clin Cancer Res. 2008 Nov 1;14(21):7060-7.
    18981003
  • Yonesaka K,Zejnullahu K,Lindeman N,Homes AJ,Jackman DM,Zhao F,Rogers AM,Johnson BE,Janne PA.Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.Clin Cancer Res. 2008 Nov 1;14(21):6963-73.
    18980991
  • Janne PA.Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?.Am J Respir Crit Care Med. 2008 Oct 15;178(8):783-5.
    18832554
  • Toschi L,Janne PA.Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.Clin Cancer Res. 2008 Oct 1;14(19):5941-6. Review.
    18829470
  • Cioffredi LA,Janne PA,Jackman DM.Treatment of peritoneal mesothelioma in pediatric patients.Pediatr Blood Cancer. 2009 Jan;52(1):127-9.
    18819151
  • Simon GR,Verschraegen CF,Janne PA,Langer CJ,Dowlati A,Gadgeel SM,Kelly K,Kalemkerian GP,Traynor AM,Peng G,Gill J,Obasaju CK,Kindler HL.Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.J Clin Oncol. 2008 Jul 20;26(21):3567-72.
    18640937
  • Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA.Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.Br J Cancer. 2008 Jul 22;99(2):245-52.
    18594528
  • Koivunen JP,Mermel C,Zejnullahu K,Murphy C,Lifshits E,Holmes AJ,Choi HG,Kim J,Chiang D,Thomas R,Lee J,Richards WG,Sugarbaker DJ,Ducko C,Lindeman N,Marcoux JP,Engelman JA,Gray NS,Lee C,Meyerson M,Janne PA.EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Clin Cancer Res. 2008 Jul 1;14(13):4275-83.
    18594010
  • Lynch TJ Jr,Blumenschein GR Jr,Engelman JA,Espinoza-Delgado I,Govindan R,Hanke J,Hanna NH,Heymach JV,Hirsch FR,Janne PA,Lilenbaum RC,Natale RB,Riely GJ,Sequist LV,Shapiro GI,Shaw A,Shepherd FA,Socinski M,Sorensen AG,Wakelee HA,Weitzman A.Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12.
    18520291
  • Ahn MJ,Park BB,Ahn JS,Kim SW,Kim HT,Lee JS,Kang JH,Cho JY,Song HS,Park SH,Sohn CH,Shin SW,Choi JH,Ki CS,Park CK,Holmes AJ,Janne PA,Park K.Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?.Clin Cancer Res. 2008 Jun 15;14(12):3860-6.
    18559606
  • Janne PA.Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.Lung Cancer. 2008 Jun;60 Suppl 2:S3-9. Review.
    18513582
  • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations.J Clin Oncol. 2008 May 20;26(15):2442-9.
    18458038
  • Engelman JA,Janne PA.Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Clin Cancer Res. 2008 May 15;14(10):2895-9. Review.
    18483355
  • Cappuzzo F, Finocchiaro G, Rossi E, Jnne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M.EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.Ann Oncol. 2008 Apr;19(4):717-23.
    17974556
  • Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.J Clin Oncol. 2008 Mar 20;26(9):1465-71.
    18349397
  • Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jnne PA.PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.Cancer Res. 2007 Dec 15;67(24):11924-32.
    18089823
  • Toschi L, Cappuzzo F, Jnne PA.Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer.Ann Oncol. 2007 Jul;18 Suppl 9:ix150-5. Review.
    17631569
  • Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA.Ras pathway activation in malignant mesothelioma.J Thorac Oncol. 2007 Sep;2(9):789-95.
    17805054
  • Jnne PA, von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, Eiseman IA, Chiappori AA, Yeap BY, Lenehan PF, Dasse K, Sheeran M, Bonomi PD.Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.J Clin Oncol. 2007 Sep 1;25(25):3936-44.
    17761977
  • Allen AM, Den R, Wong JS, Zurakowski D, Soto R, Jnne PA, Zellos L, Bueno R, Sugarbaker DJ, Baldini EH.Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1366-74.
    17674974
  • Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK.LKB1 modulates lung cancer differentiation and metastasis.Nature. 2007 Aug 16;448(7155):807-10.
    17676035
  • Johnson BE, Jackman D, Jnne PA.Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4628-31. Review.
    17671154
  • Liu W, Makrauer FL, Qamar AA, Jnne PA, Odze RD.Fulminant hepatic failure secondary to erlotinib.Clin Gastroenterol Hepatol. 2007 Aug;5(8):917-20.
    17625975
  • Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jnne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK.Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.Cancer Cell. 2007 Jul;12(1):81-93.
    17613438
  • Li J, Berbeco R, Distel RJ, Jnne PA, Wang L, Makrigiorgos GM.s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis.Nucleic Acids Res. 2007;35(12):e84.
    17545195
  • Cappuzzo F, Ligorio C, Jnne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M.Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.J Clin Oncol. 2007 Jun 1;25(16):2248-55.
    17538169
  • Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Jnne PA, Johnson BE, Chin L, Wong KK.Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.Cancer Res. 2007 May 15;67(10):4933-9.
    17510423
  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jnne PA.MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling.Science. 2007 May 18;316(5827):1039-43.
    17463250
  • Jnne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK,.Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.J Thorac Oncol. 2006 Jul;1(6):506-12.
    17409909
  • Sequist LV, Joshi VA, Jnne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.Oncologist. 2007 Jan;12(1):90-8.
    17285735
  • Jackman DM, Jnne PA.Does erlotinib improve symptoms in patients with lung cancer?.Nat Clin Pract Oncol. 2007 Mar;4(3):146-7.
    17262089
  • Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jnne PA.Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.J Clin Oncol. 2007 Mar 1;25(7):760-6.
    17228019
  • Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jnne PA, Bonomi P.Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.J Clin Oncol. 2006 Nov 20;24(33):5253-8.
    17114658
  • Johnson BE, Jackman D, Jnne PA.Impact of EGFR mutations on treatment of non-small cell lung cancer.Cancer Chemother Pharmacol. 2006 Nov;58 Suppl 7:5-9.
    17093938
  • Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jnne PA,.Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy nave patients with malignant pleural mesothelioma: outcomes of an expanded access program.Lung Cancer. 2007 Feb;55(2):187-94.
    17092602
  • Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrs AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jnne PA.Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR -amplified lung cancer.J Clin Invest. 2006 Oct;116(10):2695-706.
    16906227
  • Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jnne PA, Johnson BE.Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.J Clin Oncol. 2006 Sep 20;24(27):4517-20.
    16983123
  • Johnson BE, Jnne PA.Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer.Clin Cancer Res. 2006 Jul 15;12(14):4436s-40s. Review.
    16857824
  • Jnne PA, Johnson BE.Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.Clin Cancer Res. 2006 Jul 15;12(14):4416s-20s. Review.
    16857820
  • Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jnne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.Clin Cancer Res. 2006 Jul 15;12(14):4365s-71s.
    16857812
  • Sequist LV, Joshi VA, Jnne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.Epidermal growth factor receptor mutation testing in the care of lung cancer patients.Clin Cancer Res. 2006 Jul 15;12(14):4403s-8s. Review.
    16857818
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jnne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res. 2006 Jul 1;12(13):3908-14.
    16818686
  • Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M.Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.Nat Med. 2006 Jul;12(7):852-855.
    16799556
  • Jnne PA.Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.J Clin Oncol. 2006 Jul 20;24(21):3319-21.
    16785470
  • Allen AM, Czerminska M, Jnne PA, Sugarbaker DJ, Bueno R, Harris JR, Court L, Baldini EH.Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5.
    16751058
  • Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jnne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK.The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.Cancer Cell. 2006 Jun;9(6):485-95.
    16730237
  • Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jnne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ.Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.J Clin Oncol. 2006 Apr 1;24(10):1561-7.
    16575008
  • Jnne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE.A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8.
    16467085
  • Sattler M, Walz C, Crowley BJ, Lengfelder E, Jnne PA, Rogers AM, Kuang Y, Distel RJ, Reiter A, Griffin JD.A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples.Blood. 2006 Feb 1;107(3):1237-8.
    16434495
  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Raimes DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagri S, Hillan KJ.Mutations in the Epidermal Growth FActor Receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib.Journal of Clinical Oncology.;In press.
  • Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Jnne PA.Inhibition of the met receptor in mesothelioma.Clin Cancer Res. 2005 Nov 15;11(22):8122-30.
    16299245
  • Jiang J, Greulich H, Jnne PA, Sellers WR, Meyerson M, Griffin JD.Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.Cancer Res. 2005 Oct 1;65(19):8968-74.
    16204070
  • Greulich H, Chen TH, Feng W, Jnne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M.Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants.PLoS Med. 2005 Oct 4;2(11):e313.
    16187797
  • Johnson BE, Jnne PA.Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.Cancer Res. 2005 Sep 1;65(17):7525-9.
    16140912
  • Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jnne PA.Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94.
    16106023
  • Jnne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK.Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.Clin Lung Cancer. 2005 Jul;7(1):40-6.
    16098243
  • Jackman DM, Chirieac LR, Jnne PA.Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.Semin Respir Crit Care Med. 2005 Jun;26(3):342-52.
    16052436
  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jnne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ.Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.J Clin Oncol. 2005 Sep 1;23(25):5900-9.
    16043828
  • Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Jnne PA, Girard L, Minna J, Christiani D, Li C, Sellers WR, Meyerson M.Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.Cancer Res. 2005 Jul 1;65(13):5561-70.
    15994928
  • Jnne PA, Engelman JA, Johnson BE.Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.J Clin Oncol. 2005 May 10;23(14):3227-34.
    15886310
  • Mamon HJ, Yeap BY, Jnne PA, Reblando J, Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ, Baldini EH, Berman S, Skarin A, Bueno R.High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation.J Clin Oncol. 2005 Mar 1;23(7):1530-7.
    15735128
  • Engelman JA, Jnne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93.
    15731348
  • Kobayashi S, Boggon TJ, Dayaram T, Jnne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.N Engl J Med. 2005 Feb 24;352(8):786-92.
    15728811
  • Cho D, Kocher O, Lee JC, Tenen DG, Meyerson ML, Janne PA, Halmos B.Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.J Clin Oncol. 2005 Jan 1;23(1):235-7.
    15625379
  • Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jnne PA.Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.Cancer Res. 2004 Oct 15;64(20):7241-4.
    15492241
  • Paez JG, Jnne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy.Science. 2004 Jun 4;304(5676):1497-500.
    15118125
  • Zhao X, Li C, Paez JG, Chin K, Jnne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M.An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays.Cancer Res. 2004 May 1;64(9):3060-71.
    15126342
  • Johnson BE, Jnne PA.Basic treatment considerations using chemotherapy for patients with small cell lung cancer.Hematol Oncol Clin North Am. 2004 Apr;18(2):309-22.
    15094173
  • Jnne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE.Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.Lung Cancer. 2004 May;44(2):221-30.
    15084387
  • Wirth LJ, Carter MR, Jnne PA, Johnson BE.Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.Lung Cancer. 2004 May;44(2):213-20.
    15084386
  • Jnne PA, Li C, Zhao X, Girard L, Chen TH, Minna J, Christiani DC, Johnson BE, Meyerson M.High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines.Oncogene. 2004 Apr 8;23(15):2716-26.
    15048096
  • Jnne PA, Skarin AT.Concurrent docetaxel and thoracic radiation in non-small-cell lung cancer.Clin Lung Cancer. 2002 May;3 Suppl 2:S37-41.
    14720346
  • Means-Markwell M, Linnoila RI, Williams J, Jnne PA, Kaye F, O'Neil K, Johnson BE.Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer.Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5915-21.
    14676115
  • Jnne PA.The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma.Ann Med. 2003;35(7):450-7.
    14649327
  • Janne PA.Chemotherapy for malignant pleural mesothelioma.Clin Lung Cancer. 2003 Sep;5(2):98-106.
    14596692
  • Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jnne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT.Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.Clin Cancer Res. 2003 May;9(5):1698-704.
    12738723
  • Jnne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA, Johnson BE.Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.Cancer. 2002 Oct 1;95(7):1528-38.
    12237922
  • Jnne PA, Taffaro ML, Salgia R, Johnson BE.Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.Cancer Res. 2002 Sep 15;62(18):5242-7.
    12234991
  • Jeter MD, Jnne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, Loeffler JS, Devlin PM, Salgia R.Gemcitabine-induced radiation recall.Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):394-400.
    12023144
  • Jnne PA, Rodriguez-Thompson D, Metcalf DR, Swanson SJ, Greisman HA, Wilkins-Haug L, Johnson BE.Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: a case report and a review of chemotherapy treatment during pregnancy.Oncology. 2001;61(3):175-83.
    11574771
  • Jnne PA, Mayer RJ.Chemoprevention of colorectal cancer.N Engl J Med. 2000 Jun 29;342(26):1960-8.
    10874065